Sansure Biotech Partners with Tencent Health to Launch an AI Ecosystem for China Primary Healthcare On May 9, Sansure Biotech signed a strategic cooperation agreement with Tencent Health at..

3.3.2 Future Development of Blood Typing Instruments Working Party on Clinical Transfusion Management, Chinese Society of Blood Transfusion investigated blood transfusion departments of 2309 hospitals in differe..

H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Fujirebio Europe N.V. has obtained a CE certificate of the Lumipulse G pTau 217 Plasma assay under the Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR). This CLEIA (chemiluminescent enzyme immunoassay) test allows for the quantitative measurement of Tau phosphorylated at threonine 217 (pTau 217) in human plasma (K2EDTA).

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2026 second quarter, which ended March 31, 2026.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2026.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2026.

Original from: Roche - PathAI’s best-in-class Image Management System (IMS) with advanced AI analysis and workflow capabilities will complement Roche's digital pathology portfolio to drive laboratory eff..

Original from: Siemens Healthineers Siemens Healthineers AG today announces its results for the second quarter of fiscal year 2026 ended March 31, 2026. Q2 Fiscal Year 2026 • Eq..

Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), today announced a collaboration with Tempus AI Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, to broaden access to a novel blood-based biomarker panel designed to improve detection accuracy for Alzheimer’s disease. Through the agreement, Tempus AI will build a Tempus Next care gap program for Alzheimer’s disease blood-based biomarker testing, with the LucentAD® Complete multi-biomarker blood test becoming available for neurologists to order on the Tempus clinical ordering platform.

Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced financial results for the first quarter ended March 31, 2026.

QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced financial results for the first quarter ended March 29, 2026.

Revvity, Inc. (NYSE: RVTY), today reported financial results for the first quarter ended April 5, 2026.

3.3 Market Conditions of Blood Typing Instruments 3.3.1 Market Size of China’s Blood Typing Instruments between 2020 and 2025 Blood typing is closely associated with surgical operation volume, num..

Original from: CareDx CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differe..

Original from: PR Newswire Laguna Diagnostics, LLC today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the company's mRNA Gene Biomarker Test, ..

1. Integrated pipeline: high speed and high throughput instrument’s rigid demand of high-end hospitals and laboratories will develop towards the direction of integrated pipeline to meet high-end hospitals’ test requ..

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary results for the first quarter of 2026, continuing to deliver strong profitability as adjusted diluted earnings per share (EPS) achieved the outlook. Sales trends were mixed, as lower QuantiFERON sales and cautious U.S. Life Sciences customer demand offset solid growth in other areas of the portfolio.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has signed a definitive agreement to sell its microbiology business to Astorg, a leading pan-European private equity firm, for consideration of approximately $1.075 billion, consisting of cash and a $50 million seller note.

Several leading In Vitro Diagnostic (IVD) companies have posted their first-quarter results for 2026, showing mixed performance across revenue, profitability, and cash flow.

Original from: bioMérieux - First quarter was impacted by mild respiratory epidemiology, and by the uncertain geopolitical and macroeconomic environment which drives softness in customers’investment de..